Keeping the Government at Bay: Protecting Part D from the Protected Classes and Specialty Drug Pricing
• By Cole Werble
A tenuous collaboration between drug manufacturers and health insurance plans holds together Part D, the private Medicare drug benefit. That collaboration is coming under pressure on several fronts: specialty drug pricing and restrictions on health plan formulary tools for six specfic drug classes are the most threatening. Karen Ignagni, the head of the health industry trade group, says industry must resolve the problems or leave a hole for more government control.
By Cole Werble
Two fissures are threatening to break apart the business
coalition that makes the private Medicare drug program viable.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.
Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.